Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan

Shumpei Yokota, Ryuta Nishikomori, Hidetoshi Takada, Masako Kikuchi, Tomo Nozawa, Taichi Kanetaka, Toshitaka Kizawa, Takako Miyamae, Masaaki Mori, Toshio Heike, Toshiro Hara, Tomoyuki Imagawa

Research output: Contribution to journalReview articlepeer-review

1 Citation (Scopus)


Cryopyrin-associated periodic syndrome (CAPS) is an orphan disease with incidence of about one in 1,000,000 persons. This autoinflammatory disease develops in the neonatal period or early childhood, with various inflammatory symptoms occurring repeatedly throughout the patient's lifetime. It is caused by abnormality of the NLRP3 protein which mediates the intracellular signal transduction mechanism of inflammatory processes, resulting in continuous overproduction of interleukin (IL)-1β, which induces chronic inflammation and progressive tissue damage. Definitive diagnosis of CAPS is difficult, and treatment has also been difficult because of a lack of effective medications in Japan. Clinical studies of human anti-human IL-1β monoclonal antibody (canakinumab) treatment were conducted in Japan, and approval was granted for therapeutic use of canakinumab for CAPS in September 2011. Similar to other biological drugs, canakinumab is clinically highly effective. However, sufficient attention to the method of use and adverse drug reactions is necessary. This guidance describes the use of canakinumab in Japan for CAPS in relation to exclusion criteria, method of use, evaluation criteria, and adverse drug reactions.

Original languageEnglish
Pages (from-to)425-429
Number of pages5
JournalModern Rheumatology
Issue number3
Publication statusPublished - May 2013

All Science Journal Classification (ASJC) codes

  • Rheumatology


Dive into the research topics of 'Guidance on the use of canakinumab in patients with cryopyrin-associated periodic syndrome in Japan'. Together they form a unique fingerprint.

Cite this